Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Finasteride is a medicine used to treat enlarged prostate and prostate cancer, and it works by changing how testosterone works in the body.

This study reports that controlled release PRP therapy using dalteparin and protamine micro-particles may be effective for hair growth and skin rejuvenation in women.

Adding dalteparin and protamine microparticles to platelet-rich plasma can boost hair growth more than using platelet-rich plasma alone.

This review discusses pharmacologic and non-pharmacologic treatments for androgenetic alopecia, noting that current medications like finasteride and minoxidil can slow hair loss but only partially restore hair growth, with early treatment offering better outcomes.

This review discusses the cutaneous application of bimatoprost ophthalmic solution 0.03% for enhancing upper eyelash growth and suggests it is both safe and effective; no new clinical results are reported.

This case report highlights a rare side effect of prostaglandin analogues, detailing prostaglandin-associated periorbitopathy in three glaucoma patients treated with bimatoprost and travoprost.

This study uncovered that bimatoprost, a prostaglandin analog, promotes hair growth by activating hair follicle progenitor cells through two pathways: the PTGFR-MAPK signaling axis and an unexpected IGF1R-PCAD-AKT signaling axis, suggesting new potential targets for treating hair disorders.

This study found that treprostinil, a prostacyclin analog, significantly delayed fibroblast migration from healthy donors but did not affect fibroblast migration derived from diabetic foot ulcers.

Formestane is a preferred second-line treatment for advanced breast cancer in postmenopausal women because it's effective and has fewer side effects.

This study found that PGF2alpha analogues and PGE2 stimulated hair follicle activity in mice, with PGF2alpha analogues also linked to potential side effects like poliosis when used as eye treatments.

This case report discusses the use of a prostaglandin analogue for treating eyebrow loss in a patient with frontal fibrosing alopecia, but provides no new clinical results.

This research found that the new combination drug Predstanormix Duo, with dutasteride and tamsulosin, is bioequivalent to established treatments for benign prostatic hyperplasia, showing similar pharmacokinetics and safety, potentially improving treatment availability and adherence in high-risk patients.

This study found that two new progesterone derivatives showed higher antiandrogenic effects and 5α-reductase inhibition than finasteride in hamsters, particularly reducing seminal vesicle weight and flank organ size.

The studies reviewed found favorable treatment outcomes for hypopigmented scars using PGF2α agonists with no adverse events reported. However, the authors highlight the need for larger randomized controlled trials to better understand their effectiveness and long-term safety.

This study found that aliphatic ester moieties in 16-formyl-17-methoxy dehydroepiandrosterone derivatives increased their potency as 5α-reductase type 2 inhibitors in vitro compared to finasteride.

This study demonstrated that PGF 2α significantly stimulates hair growth in human hair follicles via a receptor-driven mechanism, with a notably stronger response in intermediate follicles than in terminal ones, suggesting potential clinical significance for conditions like alopecia.

This study found that specific steroids, particularly 5 and 7b, decreased growth of prostate and seminal vesicles and bound to the androgen receptor, showing comparable pharmacological activity to finasteride.

This article lists online educational resources from the American Society of Plastic Surgeons but reports no new research findings.

This study found that the compound androstane-17-carboxamide 6 may serve as a lead for new drugs to treat BPH and prostate cancer by reducing the weight of androgen-dependent glands.

In this study, AMP-303 injections demonstrated a trend toward increasing non-vellus hair count in men with mild to moderate androgenetic alopecia, notably showing a 14.5% peak increase at 60 days compared to saline, with effects lasting up to five months.

This review discusses the potential of prostaglandin analogs for hair growth and forms of alopecia, and reports no new clinical results.

This case report of female-pattern androgenetic alopecia found that injected bimatoprost solution did not successfully treat the condition, prompting considerations for future prostaglandin analog therapies.

This study found that pregnane derivatives with higher lipophilicity, like compound 9d, had stronger androgen receptor binding and greater antiandrogenic effects in rats, correlating relative binding affinity with log P values.

This study found that the peptides RMYYY and VMYMI displayed stronger binding energy and more frequent interactions with HPGDS compared to the native inhibitor, suggesting potential as future therapeutic drugs.

This study reported that newly synthesized progesterone derivatives significantly reduced prostate weight in testosterone-treated hamsters, with 5alpha-reductase inhibitory activity dependent on the size of the substituent at C-17.

This study found that four new progesterone derivatives reduced prostate weight in gonadectomized hamsters, suggesting potent in vivo antiandrogenic effects similar to finasteride.

In this study, researchers developed and tested a novel peptide, AMHR2BP, which mimics the function of Anti-Müllerian hormone to protect ovarian follicles in mice, showing promise for preserving ovarian health during chemotherapy without causing toxicity.

This study found that several new pregnane derivatives, especially steroids 16 and 19, demonstrated higher antiandrogenic activity on male hamster models than the commonly used finasteride.

This study suggests that PF-0998425 is an effective androgen receptor antagonist for sebum control and androgenetic alopecia with rapid metabolism reducing the risk of systemic side effects.